Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

By Neil Gupta, B. Limbago, J. Patel, A. Kallen. Clinical Infectious Diseases, 2011

1,016 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Homeostatic immunity and the microbiota (2017, neutral): “Author manuscript; available in PMC 2018 April 18. worldwide (Gupta et al., 2011).”
ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. (2014, background): “Is o la ti o n ro o m 2 [1 2 6 ,1 2 7 ] 3 [2 8 5 – 8 7 ] 1 [2 7 8 ] M o d e ra te 3 [1 2 3 ,1 2 4 ,2 7 9 ] 4 [1 2 8 ,2 8 0 ,2 8 1 ,2 8 3 ] 2 [6 2 ,2 8 4 ] M o d e ra te”
Nucleic acid detection with CRISPR-Cas13a/C2c2 (2017, neutral): “Additionally,wewere able to use SHERLOCK to distinguish between clinical isolates of Klebsiella pneumoniae with two different resistance genes: Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-b-lactamase 1 (NDM-1) (21) (fig.”
Role of the Microbiota in Immunity and inflammation (2014, background): “Infections caused by multidrug-resistant organisms are on the rise and have developed into endemic and epidemic situations worldwide (Gupta et al., 2011).”
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. (2012, result): “Two (ie, presence of septic shock and high APACHE III score) were related to the clinical status of the patient at infection onset, and these findings are consistent with previous reports [12, 15, 28, 31].”